{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:59:44Z","timestamp":1790657984971,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2023.e23752","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T22:18:56Z","timestamp":1702678736000},"page":"e23752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["KRM\u2013II\u201381 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9145-8548","authenticated-orcid":false,"given":"Jodi L.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Wertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Lippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjie","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Witkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-6398","authenticated-orcid":false,"given":"Rok","family":"Cerne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e23752_bib1","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.4103\/0972-2327.128688","article-title":"Epileptogenic networks and drug-resistant epilepsy: present and future perspectives of epilepsy research-Utility for the epileptologist and the epilepsy surgeon","volume":"17","author":"Banerjee","year":"2014","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.heliyon.2023.e23752_bib2","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e23752_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.17712\/1658-3183.1826","article-title":"Definition of intractable epilepsy","volume":"16","author":"Sinha","year":"2011","journal-title":"Neurosciences"},{"key":"10.1016\/j.heliyon.2023.e23752_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1042-3680(18)30437-6","article-title":"Epidemiology of epilepsy in children","volume":"6","author":"Hauser","year":"1995","journal-title":"Neurosurg. Clin."},{"issue":"Suppl 4","key":"10.1016\/j.heliyon.2023.e23752_bib5","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1111\/j.1528-1157.1992.tb06222.x","article-title":"Seizure disorders: the changes with age","volume":"33","author":"Hauser","year":"1992","journal-title":"Epilepsia"},{"key":"10.1016\/j.heliyon.2023.e23752_bib6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000056036","article-title":"Temporal lobectomy in children with intractable seizures","volume":"34","author":"Adelson","year":"2001","journal-title":"Pediatr. Neurosurg."},{"key":"10.1016\/j.heliyon.2023.e23752_bib7","series-title":"New and Emerging Antiepileptic Drugs. Burger's Medicinal Chemistry, Drug Discovery and Development","author":"Witkin","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e23752_bib8","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1528-1167.2006.00607.x","article-title":"Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs","volume":"47","author":"L\u00f6scher","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.heliyon.2023.e23752_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/jpet.119.260968","article-title":"The positive allosteric modulator of \u03b12\/3-containing GABAA receptors, KRM-II-81, is active in pharmaco-resistant models of epilepsy and reduces hyperexcitability after traumatic brain injury","volume":"372","author":"Witkin","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.heliyon.2023.e23752_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172996","article-title":"The \u03b12,3-selective potentiators of GABAA receptors, KRM-II-81 and MP-III-80, produce anxiolytic-like effects and block chemotherapy-induced hyperalgesia in mice without tolerance development","volume":"196","author":"Biggerstaff","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.heliyon.2023.e23752_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.114.212779","article-title":"Perampanel, an antagonist of \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models","volume":"351","author":"Zwart","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.heliyon.2023.e23752_bib12","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/WNP.0b013e3181fdf8d3","article-title":"Aberrant neuronal avalanches in cortical tissue removed from juvenile epilepsy patients","volume":"27","author":"Hobbs","year":"2010","journal-title":"J. Clin. Neurophysiol."},{"key":"10.1016\/j.heliyon.2023.e23752_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173321","article-title":"The imidazodiazepine, KRM-II-81: an example of a newly emerging generation of GABAkines for neurological and psychiatric disorders","author":"Witkin","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.heliyon.2023.e23752_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","article-title":"Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Knight","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.heliyon.2023.e23752_bib15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neuropharm.2018.05.006","article-title":"Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: improved bioavailability enhances anticonvulsant efficacy","volume":"137","author":"Witkin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.heliyon.2023.e23752_bib16","article-title":"GABAkines - advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors","author":"Cerne","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2023.e23752_bib17","doi-asserted-by":"crossref","first-page":"10800","DOI":"10.1021\/acs.jmedchem.6b01332","article-title":"Synthesis and characterization of a novel gamma-aminobutyric acid type A (GABAA) receptor ligand that combines outstanding metabolic stability, pharmacokinetics, and anxiolytic efficacy","volume":"59","author":"Poe","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.heliyon.2023.e23752_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pbb.2019.02.013","article-title":"The \u03b12,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats","volume":"180","author":"Witkin","year":"2019","journal-title":"Pharmacol. Biochem. Behav."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023109601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023109601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:51:51Z","timestamp":1790657511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023109601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844023109601"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23752","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KRM\u2013II\u201381 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e23752"}}